Barclays PLC grew its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC – Free Report) by 362.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 170,546 shares of the medical technology company’s stock after acquiring an additional 133,653 shares during the quarter. Barclays PLC’s holdings in Alphatec were worth $948,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of ATEC. XTX Topco Ltd purchased a new stake in Alphatec during the 3rd quarter valued at about $69,000. Net Worth Advisory Group bought a new position in shares of Alphatec in the third quarter worth approximately $76,000. Van ECK Associates Corp grew its holdings in shares of Alphatec by 57.0% during the third quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock valued at $99,000 after buying an additional 6,998 shares during the last quarter. Tempus Wealth Planning LLC bought a new stake in shares of Alphatec during the third quarter valued at approximately $107,000. Finally, Atria Investments Inc raised its holdings in Alphatec by 8.0% in the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock worth $109,000 after acquiring an additional 1,460 shares during the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.
Wall Street Analyst Weigh In
ATEC has been the topic of several recent analyst reports. Barclays increased their target price on Alphatec from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Tuesday, November 19th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research report on Tuesday. Finally, Needham & Company LLC lifted their price objective on Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a report on Monday. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Alphatec presently has a consensus rating of “Moderate Buy” and an average price target of $17.44.
Insiders Place Their Bets
In other news, EVP David Sponsel sold 58,283 shares of Alphatec stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $10.71, for a total value of $624,210.93. Following the completion of the transaction, the executive vice president now owns 502,311 shares in the company, valued at approximately $5,379,750.81. The trade was a 10.40 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 22.80% of the company’s stock.
Alphatec Stock Up 2.2 %
ATEC opened at $11.12 on Wednesday. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $17.34. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The firm has a 50-day simple moving average of $9.49 and a two-hundred day simple moving average of $8.00. The company has a market capitalization of $1.58 billion, a PE ratio of -8.69 and a beta of 1.41.
Alphatec Profile
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.
Read More
- Five stocks we like better than Alphatec
- Why Invest in 5G? How to Invest in 5G Stocks
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- ESG Stocks, What Investors Should Know
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Want to see what other hedge funds are holding ATEC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alphatec Holdings, Inc. (NASDAQ:ATEC – Free Report).
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.